André Thá Nassif1, Thais Ayumi Nagano2, Sulamita Okayama3, Luís Sérgio Nassif3, Alcides Branco Filho3, José Sampaio Neto3. 1. Hopital Santa Casa de Misericórdia de Curitiba, Praça Rui Barbosa, 694 - Centro, Curitiba, PR, 80010-030, Brazil. andre-nassif@hotmail.com. 2. Pontifícia Universidade Católica do Paraná, Curitiba, Brazil. 3. Hopital Santa Casa de Misericórdia de Curitiba, Praça Rui Barbosa, 694 - Centro, Curitiba, PR, 80010-030, Brazil.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease incidence is related to the presence of obesity and insulin resistance. A treatment of this disease in patients with morbid obesity is bariatric surgery and its diagnosis is extremely important due to the possible progression to cirrhosis or hepatocellular carcinoma. The development of clinical-laboratorial analysis tools to this disease and its complications is necessary as the gold standard for its diagnosis is an invasive procedure. The objective of the study is to evaluate the use of BARD score in the selection of patients who should undergo liver biopsy during bariatric surgery. METHODS: It was a retrospective analysis of patients with hepatic disease who were biopsied between 2012 and 2013. Their clinical and laboratory data were analyzed by BARD score. The results of those who presented score >2 were compared to the rest. RESULTS: Two hundred ninety-eight patients with hepatic disease were analyzed and among them 70.27 % had score >2. Of the 76 patients with score <1, 1 was diagnosed with liver fibrosis, determining a negative predictive value of 98.68 % for the test (p < 0.05). CONCLUSIONS: The BARD score is still not ideal for the diagnosis of nonalcoholic fatty liver disease, hepatitis, and fibrosis, but it was proved to be effective in the detection of absence of liver fibrosis in a bariatric population.
BACKGROUND:Nonalcoholic fatty liver disease incidence is related to the presence of obesity and insulin resistance. A treatment of this disease in patients with morbid obesity is bariatric surgery and its diagnosis is extremely important due to the possible progression to cirrhosis or hepatocellular carcinoma. The development of clinical-laboratorial analysis tools to this disease and its complications is necessary as the gold standard for its diagnosis is an invasive procedure. The objective of the study is to evaluate the use of BARD score in the selection of patients who should undergo liver biopsy during bariatric surgery. METHODS: It was a retrospective analysis of patients with hepatic disease who were biopsied between 2012 and 2013. Their clinical and laboratory data were analyzed by BARD score. The results of those who presented score >2 were compared to the rest. RESULTS: Two hundred ninety-eight patients with hepatic disease were analyzed and among them 70.27 % had score >2. Of the 76 patients with score <1, 1 was diagnosed with liver fibrosis, determining a negative predictive value of 98.68 % for the test (p < 0.05). CONCLUSIONS: The BARD score is still not ideal for the diagnosis of nonalcoholic fatty liver disease, hepatitis, and fibrosis, but it was proved to be effective in the detection of absence of liver fibrosis in a bariatric population.
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Antônio Roberto Franchi Teixeira; Marta Bellodi-Privato; José Barreto Carvalheira; Victor Fernando Pilla; José Carlos Pareja; Luiz Augusto Carneiro D'Albuquerque Journal: Obes Surg Date: 2009-12 Impact factor: 4.129
Authors: Soraya Rodrigues de Almeida; Paulo Roberto Savassi Rocha; Marcelo Dias Sanches; Virgínia Hora Rios Leite; Rogério Augusto Pinto da Silva; Marco Túlio Costa Diniz; Maria de Fátima Haueisen Sander Diniz; Alexandre Lages Savassi Rocha Journal: Obes Surg Date: 2006-03 Impact factor: 4.129
Authors: Alexandre Coutinho Teixeira de Freitas; Antonio Carlos Ligocki Campos; Julio Cezar Uili Coelho Journal: Curr Opin Clin Nutr Metab Care Date: 2008-05 Impact factor: 4.294
Authors: Sherene Shalhub; Anna Parsee; Scott F Gallagher; Krista L Haines; Chris Willkomm; Stephen G Brantley; Haim Pinkas; Lisa Saff-Koche; Michel M Murr Journal: Obes Surg Date: 2004-01 Impact factor: 4.129
Authors: Sami Qadri; Noora Ahlholm; Ida Lønsmann; Paola Pellegrini; Anni Poikola; Panu K Luukkonen; Kimmo Porthan; Anne Juuti; Henna Sammalkorpi; Anne K Penttilä; Roberta D'Ambrosio; Giorgio Soardo; Diana J Leeming; Morten Karsdal; Johanna Arola; Stergios Kechagias; Serena Pelusi; Mattias Ekstedt; Luca Valenti; Hannes Hagström; Hannele Yki-Järvinen Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134